Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial
| Autor: | Tetsuya Fujikawa, Hiromichi Wakui, Kengo Azushima, Tomoyuki Kawano, Satoshi Yamaguchi, Hiroshi Mitsuhashi, Toshimasa Ohnishi, Kouichi Tamura, Eiko Ueda, Tadashi Kuji, Yoshiyuki Toya, Yuki Kawai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
continuous erythropoietin receptor activator Anemia Endocrinology Diabetes and Metabolism medicine.medical_treatment 030204 cardiovascular system & hematology Gastroenterology law.invention Hemoglobins 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Renal Dialysis Interquartile range law Internal medicine Internal Medicine medicine Clinical endpoint Humans iron metabolism Erythropoiesis 030212 general & internal medicine Erythropoietin Original Paper business.industry medicine.disease erythropoietin‐stimulating agent Continuous erythropoietin receptor activator Hypertension Hematinics Hemoglobin Hemodialysis Cardiology and Cardiovascular Medicine business japanese hemodialysis patients renal anemia |
| Zdroj: | The Journal of Clinical Hypertension |
| ISSN: | 1751-7176 1524-6175 |
| Popis: | Although continuous erythropoietin receptor activators (CERAs) are widely used erythropoiesis‐stimulating agents for correcting renal anemia in patients undergoing hemodialysis (HD), few reports have examined weekly CERA administration. In this randomized controlled trial, we compared the efficacy and changes in the parameters of iron metabolism and erythropoiesis between weekly and biweekly CERA administration. In total, 120 patients undergoing maintenance HD were randomized to the weekly or biweekly group. The primary end point was the total CERA dose needed to maintain the target hemoglobin (Hb) levels during a 12‐week evaluation period. There was no significant difference in the total dose between the weekly and biweekly groups (median 175.0 [interquartile range (IQR) 93.8–337.5] µg/12 weeks vs. 300.0 [IQR 125.0–375.0] µg/12 weeks, P = .18). The mean Hb levels during the evaluation period were 10.9 ± 0.8 g/dL in the weekly group and 10.7 ± 0.8 g/dL in the biweekly group (P = .25). Weekly CERA administration was well tolerated. Weekly CERA administration similarly managed anemia as biweekly administration in patients undergoing HD. Patients undergoing hemodialysis were randomized to once‐weekly or biweekly continuous erythropoietin receptor activator (CERA) treatment for 12 weeks. There were no differences in the total CERA dose to maintain hemoglobin levels between two groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text